- -

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

RiuNet: Institutional repository of the Polithecnic University of Valencia

Share/Send to

Cited by

Statistics

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

Show full item record

Iranzo, V.; Sirera Pérez, R.; Carrato, A.; Cabrera, A.; Jantus, E.; Guijarro, R.; Sanmartín, E.... (2011). Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical & Translational Oncology. 13(6):411-418. doi:10.1007/s12094-011-0675-0

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/65054

Files in this item

Item Metadata

Title: Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
Author:
UPV Unit: Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia
Issued date:
Abstract:
[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...[+]
Subjects: EGFR , HTERT , Non-small-cell lung cancer , Pharmacogenomics , Sequential monotherapy , VEGF , Epidermal growth factor receptor , Gemcitabine , Paclitaxel , Telomerase reverse transcriptase , Vasculotropin , Adult , Advanced cancer , Aged , Alopecia , Anemia , Anorexia , Article , Blood toxicity , Cancer staging , Cancer survival , Chemotherapy induced emesis , Clinical article , Controlled study , Diarrhea , Dose response , Drug dose reduction , Drug dose sequence , Drug efficacy , Drug hypersensitivity , Drug tolerability , Drug withdrawal , Enzyme blood level , Fatigue , Febrile neutropenia , Female , Heart disease , Human , Lung non small cell cancer , Male , Monotherapy , Multicenter study , Multiple cycle treatment , Mutational analysis , Nausea , Neuropathy , Neutropenia , Oncogene K ras , Overall survival , Paresthesia , Peripheral neuropathy , Phase 2 clinical trial , Primary health care , Prognosis , Protein blood level , Quality of life , Sensory neuropathy , Survival time , Thrombocytopenia , Treatment duration , Treatment response , Adenocarcinoma , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Large Cell , Carcinoma, Non-Small-Cell Lung , Carcinoma, Squamous Cell , Deoxycytidine , Humans , Lung Neoplasms , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local , Survival Rate , Treatment Outcome
Copyrigths: Cerrado
Source:
Clinical & Translational Oncology. (issn: 1699-048X )
DOI: 10.1007/s12094-011-0675-0
Publisher:
Springer
Publisher version: https://dx.doi.org/10.1007/s12094-011-0675-0
Type: Artículo

References

Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353 [+]
Rapp E, Pater JL, Willan A et al (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353

(1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899–909

Rixe O, Gatineau M, Jauffret E et al (2005) Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Bull Cancer 92:E1–E6

Norton L, Day R (1991) Potential innovations in scheduling of cancer chemotherapy. Important Adv Oncol 57–72

Grossi F, Aita M, Follador A et al (2007) Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 12:451–464

Poon D, Foo KF, Chew L et al (2006) Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer. Ann Acad Med Singapore 35:33–37

Hirsh V, Latreille J, Kreisman H et al (2005) Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities: a multicenter phase II trial. Lung Cancer 49:117–123

Hesketh PJ, Chansky K, Lau DH et al (2006) Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 1:537–544

Marsland TA, Garfield DH, Khan MM et al (2005) Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Lung Cancer 47:111–120

Martoni AA, Bernardi A, Quercia S (2006) Trastuzumab plus estrogen suppression as salvage treatment in a case of liver failure due to metastatic breast cancer. Anticancer Res 26:3739–3744

Camps C, Sirera R, Bremnes RM et al (2006) Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancer. Anticancer Res 26:4905–4909

Camps C, Sirera R, Bremnes R et al (2005) Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer 50:339–346

Crowley J, Pauler DA (2006) Handbook of statistics in clinical oncology. Chapman & Hall/CRC, Boca Raton, FL, pp 289–333

Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631

Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367

Day RS (1986) Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 46:3876–3885

Feliu J, Martin G, Lizon J et al (2001) Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatingemcitabine-vinorelbine. A phase II study. Ann Oncol 12:1369–1374

Edelman MJ, Clark JI, Chansky K et al (2004) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022–5026

Manegold C, Thatcher N, Kortsik C et al (2005) A phase II/III randomized study in advanced nonsmall cell lung cancer (NSCLC) with first line combination versus sequential gemcitabine (G) and docetaxel (D): update on quality of life (QoL), toxicity, and costs. J Clin Oncol 23(16S):7057

Ramanathan RK, Belani CP (1997) Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol 24:440–454

Gatzemeier U, Shepherd FA, Le Chevalier T et al (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A:243–248

Cerny T, Kaplan S, Pavlidis N et al (1994) Docetaxel (Taxotere) is active in nonsmall-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384–387

Viens P, Palangie T, Janvier M et al (1999) Firstline high-dose sequential chemotherapy with rGCSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer 81:449–456

Wandt H, Birkmann J, Denzel T et al (1999) Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23:763–770

Bonadonna G (1992) Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127–2137

Delbaldo C, Michiels S, Syz N et al (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-smallcell lung cancer: a meta-analysis. JAMA 292: 470–484

Gralla RJ, Thatcher N (2004) Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer 46[Suppl 2]:S41–S47

Spano JP, Lagorce C, Atlan D et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16:102–108

Selvaggi G, Novello S, Torri V et al (2004) Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 15:28–32

Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143–158

Laack E, Kohler A, Kugler C et al (2002) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13:1550–1557

[-]

This item appears in the following Collection(s)

Show full item record